



**RNS REACH: RELEASE**

**24 June 2026**

**ImmuPharma PLC**  
("ImmuPharma" or the "Company")

**University of Murcia research relating to P140**

ImmuPharma plc (LSE AIM: IMM), the specialist drug discovery and development company, notes the recent article published in the scientific journal *Autophagy*, which reports early-stage research conducted by the University of Murcia ("UoM") relating to the P140 peptide and its potential application in glioblastoma, an aggressive form of brain cancer.

ImmuPharma acknowledges the quality of the scientific work conducted by the UoM in this area and confirms that it has been aware of, and has followed, this research since 2024 and is in regular contact with the research team at UoM. These findings are supportive of ImmuPharma's broader scientific work on P140 and are consistent with the scientific rationale underlying the program.

P140 remains ImmuPharma's lead asset, and the Company's primary focus continues to be the advancement of P140 in autoimmune disease.

Further updates will be provided to the market when appropriate.

Ends

**ImmuPharma PLC ([www.immupharma.co.uk](http://www.immupharma.co.uk))**

Tim McCarthy, Chief Executive Officer and Chairman  
Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

**SPARK Advisory Partners Limited (NOMAD)**

Neil Baldwin

+44 (0) 203 368 8974

**Stanford Capital Partners (Joint Broker)**

Patrick Claridge, Bob Pountney

+44 (0) 203 650 3650

**SI Capital (Joint Broker)**

Nick Emerson

+44 (0) 1483 413500

**Notes to Editors**

**About ImmuPharma PLC**

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.

For additional information about ImmuPharma please visit [www.immupharma.co.uk](http://www.immupharma.co.uk).

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

**About Reach announcements**

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.